Bladder cancer
S1806
SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive
Trial overview
Topic
S1806
Disease
Bladder cancer treatment and diagnosis
Description
Primary Objective:To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).Patient Population:Patients with muscle invasive bladder cancer (MIBC) (T2-T4aN0M0).
Contact
Physicians
Frank A. Vicini
MD, FACR, FASTRO, FABS
Radiation Oncologist
Farmington Hills (Radiation oncology) +2
